Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sampat, Keeran R
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer	Active, not recruiting	2	234	Europe, US, RoW	Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care	Agenus Inc.	Metastatic Colorectal Cancer	02/25	07/25
1-BETTER, NCT04825288: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer	Active, not recruiting	1/2	76	US	XB2001 or Placebo	XBiotech, Inc.	Pancreatic Cancer	10/23	06/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sampat, Keeran R
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer	Active, not recruiting	2	234	Europe, US, RoW	Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care	Agenus Inc.	Metastatic Colorectal Cancer	02/25	07/25
1-BETTER, NCT04825288: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer	Active, not recruiting	1/2	76	US	XB2001 or Placebo	XBiotech, Inc.	Pancreatic Cancer	10/23	06/25